Male Sexual Health — Cost, Top Hospitals & Success Rates | MyMedicPlus

Male sexual health encompasses a broad spectrum of conditions affecting sexual function, satisfaction, and quality of life. The principal domains include erectile function, ejaculatory function, penile anatomy (Peyronie's disease), androgen status (hypogonadism/low testosterone), and psychosexual wellbeing. These conditions frequently co-exist and share common vascular, neurological, hormonal, and psychosocial risk factors.

Sexual dysfunction affects men across all age groups but is more prevalent with advancing age, cardiometabolic disease, depression, and hormonal decline. The Massachusetts Male Aging Study (MMAS) demonstrated that approximately 52% of men aged 40–70 experience some degree of erectile dysfunction (ED), with complete ED present in 10% and increasing with age. Addressing male sexual health requires a holistic, multidisciplinary approach incorporating urology, endocrinology, cardiology (given the close link between ED and cardiovascular risk), and psychosexual medicine.

A thorough evaluation includes a structured sexual history, the International Index of Erectile Function (IIEF-5) or Sexual Health Inventory for Men (SHIM) questionnaire, physical examination, fasting glucose, lipid profile, full blood count, and a morning testosterone level (total and free) on at least two occasions.

1. Erectile Dysfunction (ED)
ED is defined as the consistent or recurrent inability to attain and/or maintain a penile erection sufficient for satisfactory sexual performance for at least 3 months. Causes are classified as:

• Vasculogenic (most common): Arteriogenic (atherosclerosis of cavernous arteries) or venogenic (corporal veno-occlusive dysfunction). ED is a sentinel marker of subclinical cardiovascular disease — risk equivalent to mild angina per Princeton Consensus III; always screen for CV risk factors.
• Neurogenic: Diabetes mellitus neuropathy, multiple sclerosis, Parkinson's disease, pelvic surgery (radical prostatectomy — cavernous nerve injury).
• Hormonal: Hypogonadism, hyperprolactinaemia, hypothyroidism.
• Psychogenic: Performance anxiety, relationship discord, depression, PTSD — often a co-contributing factor even in organic ED.
• Medication-induced: Antidepressants (SSRIs), antihypertensives (beta-blockers, thiazides), antipsychotics, anti-androgens.

2. Premature Ejaculation (PE)
The ISSM 2014 definition of lifelong PE: ejaculation that always or nearly always occurs within approximately 1 minute of vaginal penetration (IELT <1 minute), with inability to delay, and associated bother/distress. Lifelong PE has a neurobiological basis (serotonin transporter gene polymorphism); acquired PE is often secondary to ED, prostatitis, or psychosexual factors.

3. Peyronie's Disease (PD)
An acquired connective tissue disorder of the tunica albuginea causing fibrous plaque formation, penile curvature (≥30° in most surgical series), pain (usually in acute phase <12 months), and erectile dysfunction (40–50% of men with PD). Estimated prevalence 3–9% of men; underdiagnosed.

4. Male Hypogonadism / Low Testosterone
Primary hypogonadism (testicular failure: Klinefelter syndrome, orchitis, chemotherapy) or secondary (pituitary/hypothalamic: hyperprolactinaemia, haemochromatosis, opioid use, ageing-related). Clinically significant low testosterone: <300 ng/dL (10.4 nmol/L) on two fasting morning samples, with symptoms (low libido, fatigue, reduced morning erections, mood changes, loss of muscle mass).

5. Other Conditions
Delayed ejaculation, anejaculation (absent emission), painful ejaculation (haematospermia, prostatitis), and STI-related sexual dysfunction. STI screening (HIV, chlamydia, gonorrhoea, syphilis, hepatitis B/C) is an integral part of the male sexual health consultation.

• PDE5 inhibitors (ED first-line): All men with ED without an absolute contraindication. Absolute contraindication: concurrent use of organic nitrates (any formulation) or soluble guanylate cyclase stimulators (riociguat) — potentially fatal hypotension. Use with caution in severe cardiovascular disease, recent MI or stroke (<6 weeks), unstable angina, uncontrolled hypertension. The Princeton Consensus III grading system (low/intermediate/high cardiac risk) guides safe prescribing in men with heart disease.
• Alprostadil intracavernosal injection (ED second-line): Men who fail or are intolerant of PDE5 inhibitors. Requires training in self-injection technique. Contraindicated in anticoagulation therapy (relative), penile prosthesis, or history of priapism.
• Vacuum erection device (ED): Suitable for all men with ED, particularly the elderly, those on anticoagulants, those who prefer non-pharmacological therapy, or those in whom PDE5 inhibitors are contraindicated. Effective in ~90% of men regardless of ED aetiology.
• Penile prosthesis (ED third-line): Men with ED refractory to all non-surgical treatments, or men with Peyronie's disease requiring simultaneous curvature correction and rigidity restoration. Must understand and accept the irreversible nature of the procedure.
• Dapoxetine (PE): Men with lifelong or acquired PE (IELT <2 minutes), causing bother, aged 18–64. Not recommended in hepatic impairment, cardiac disease, or with MAOIs/SSRIs/thioridazine (serotonin syndrome risk).
• Collagenase CCH (Peyronie's disease): Men in the stable (chronic) phase of PD (>12 months from onset), palpable plaque, curvature ≥30° and ≤90°, adequate erectile function (spontaneous or pharmacologically assisted) for treatment cycles.
• Testosterone replacement therapy (TRT — hypogonadism): Men with confirmed hypogonadism (two low morning testosterone levels + symptoms), after ruling out secondary reversible causes (hyperprolactinaemia, obesity, opioids, haemochromatosis). Not for men currently seeking fertility — TRT suppresses spermatogenesis.

Erectile Dysfunction — Stepwise Management

First-Line: PDE5 Inhibitors
Phosphodiesterase type 5 inhibitors block the degradation of cyclic GMP in cavernosal smooth muscle, prolonging nitric oxide–mediated vasodilation and enhancing erection in response to sexual stimulation. Four agents are approved:

• Sildenafil (Viagra): 25–100 mg on-demand; onset 30–60 minutes; duration 4–6 hours. Food reduces absorption (take on empty stomach for faster onset).
• Tadalafil (Cialis): 10–20 mg on-demand OR 2.5–5 mg once daily (allows spontaneous sexual activity). Duration 24–36 hours. Food does not significantly affect absorption. Also approved for BPH-LUTS.
• Vardenafil (Levitra): 5–20 mg on-demand; onset 25–60 minutes; duration 4–6 hours. Avoid with Class IA/III antiarrhythmics.
• Avanafil (Stendra): 50–200 mg on-demand; fastest onset (~15 minutes); fewer visual side effects (less PDE6 selectivity). Minimal food interaction.

Overall efficacy of PDE5 inhibitors: 65–80% of men with mild-to-moderate ED achieve satisfactory erections. Efficacy is lower in severe ED, post-radical prostatectomy (bilateral nerve-sparing improves outcomes), and diabetic neuropathy. Side effects: headache, flushing, nasal congestion, dyspepsia, visual disturbance (transient blue-green tinge with sildenafil — PDE6 effect), back pain and myalgia (tadalafil).

Second-Line: Intracavernosal Alprostadil (ICI)
Alprostadil (prostaglandin E1) injected directly into the corpus cavernosum causes smooth muscle relaxation independent of sexual stimulation. Starting dose: 2.5 mcg, titrated to 5–40 mcg. Efficacy: 70–85% across all ED aetiologies, including men with failed PDE5 inhibitors. Response in diabetic neuropathy and post-prostatectomy ED is significantly higher than with oral agents. Side effects: penile pain (most common, ~30%), priapism (<1% — requires emergency management if erection >4 hours), penile fibrosis with chronic use. Intraurethral alprostadil (MUSE suppository) is a less effective alternative for men who cannot or will not self-inject.

Vacuum Erection Device (VED)
A mechanical device that creates negative pressure around the penis, drawing blood into the corpora cavernosa; a constriction ring is placed at the base to maintain erection. Effective in ~90% of men. Disadvantage: erection is 'cold' (distal to the ring), unnatural pivoting, ring discomfort, ejaculatory difficulty. Widely used in elderly couples and men contraindicated for pharmacotherapy.

Third-Line: Inflatable Penile Prosthesis (IPP)
Surgical implantation of a three-piece inflatable device (cylinders in corpora + scrotal pump + reservoir). Patient satisfaction: 92–98% in appropriately selected men (AMS 700 CX / Coloplast Titan series). Irreversible — permanently destroys remaining erectile tissue. Complications: mechanical failure (~5–7% at 5 years), infection (2–3%; antibiotic-coated devices have reduced infection rates to <1%), device malposition. Post-radical prostatectomy ED is a common indication; concurrent Peyronie's correction (modelling) can be performed simultaneously.

Premature Ejaculation — Treatment

• Dapoxetine (Priligy): A short-acting SSRI developed specifically for on-demand PE treatment. Dose: 30 mg (titrate to 60 mg if tolerated) taken 1–3 hours before intercourse. Phase III trials (IELT data): geometric mean IELT improved from ~0.9 min at baseline to ~3.1 min with 60 mg dapoxetine — a 3–4-fold increase. Side effects: nausea (~20%), dizziness, headache, diarrhoea. Orthostatic hypotension shortly after dosing — avoid driving within 4 hours.
• Daily SSRI therapy (off-label): Paroxetine 10–40 mg, sertraline 50–200 mg, fluoxetine 20–40 mg, or clomipramine 10–50 mg daily. Ejaculatory delay occurs as a class effect but requires daily dosing and carries full SSRI side-effect burden (sexual desire reduction, mood effects, discontinuation syndrome).
• Topical anaesthetic: Lidocaine/prilocaine cream (EMLA 2.5% each) or lidocaine 4% spray applied to glans 20–30 minutes pre-intercourse; washed off before intercourse to avoid partner numbness. Reduces glans sensitivity and prolongs IELT.
• Behavioural techniques: Stop-start technique (Semans): stimulation is stopped at point of ejaculatory inevitability and restarted after arousal subsides; repeated over multiple sessions. Squeeze technique (Masters and Johnson): partner squeezes glans firmly for 4 seconds at point of inevitability. Both require partner cooperation; effective in psychogenic PE but labour-intensive.

Peyronie's Disease — Treatment

• Collagenase Clostridium histolyticum (CCH / Xiaflex): The only FDA/EMA-approved pharmacotherapy for PD. Bacterial collagenase injected directly into the plaque breaks down excess collagen. IMPRESS I and II trials (Gelbard et al., 2013, NEJM): CCH reduced penile curvature by 34% vs 18.2% with placebo (p<0.0001) and reduced PD symptom bother scores significantly. Protocol: up to 4 treatment cycles of 2 injections 24–72 hours apart, with modelling (manual penile straightening) between injections. Side effects: bruising, pain, penile oedema, ecchymosis. Serious: corporal rupture (<1%) — patients must avoid sexual activity for 4 weeks after each cycle.
• Surgical management: Reserved for stable-phase PD (>12 months), no spontaneous pain, and curvature stable for >3 months. Options: (a) Plication (Nesbit/modified Nesbit): suture correction on the convex side; simple and reliable, appropriate for curvature <60° with adequate penile length; shortens the penis by 1–1.5 cm. (b) Plaque incision/excision and grafting: for severe curvature (>60°) or biplanar/complex deformity; graft materials include pericardium, small intestinal submucosa (SIS), dermis — preserves length but risks ED. (c) Inflatable penile prosthesis (IPP): For men with both PD and significant ED; simultaneous modelling corrects curvature and restores rigidity — patient satisfaction >90%.

Hypogonadism / Low Testosterone

• Testosterone replacement therapy (TRT): Available as intramuscular injections (testosterone enanthate/cypionate 200 mg every 2 weeks or testosterone undecanoate 1,000 mg every 10–14 weeks), transdermal gel (testogel, Androgel 1.62%), patch (Androderm), buccal tablet, or subcutaneous pellet. Target: serum testosterone in mid-normal range (400–700 ng/dL). Monitor haematocrit (stop if >54%), PSA (in men ≥40), lipid profile, and bone mineral density.
• Lifestyle interventions: Weight loss (BMI reduction of 4–5 units raises testosterone by ~80–100 ng/dL), exercise (resistance training), sleep optimisation, and cessation of opioids/alcohol are first-line for men with obesity-related hypogonadism before initiating TRT.

Psychosexual Counselling
Integral to treatment of all male sexual dysfunction. Cognitive-behavioural therapy (CBT), sensate focus exercises (Masters and Johnson), and couples therapy address anxiety, relationship discord, unrealistic expectations, performance fears, and body image. Psychological factors perpetuate and amplify organic sexual dysfunction — even where the primary cause is physical, psychological support significantly improves outcomes and patient satisfaction.

STI Screening and Sexual Health
Annual STI screening (HIV, chlamydia, gonorrhoea, syphilis) for sexually active men, especially those with multiple partners or men who have sex with men (MSM). Hepatitis B vaccination if not immune. HPV vaccination up to age 45. Chlamydia and gonorrhoea are the most common bacterial STIs and key causes of epididymo-orchitis, urethral stricture, and male infertility.

• Restoration of erectile function: PDE5 inhibitors restore satisfactory erections in 65–80% of men with mild-to-moderate ED; intracavernosal alprostadil achieves efficacy in 70–85%; penile prosthesis achieves satisfaction in >92% of carefully selected men.
• Cardiovascular risk reduction: Identifying and treating the vascular risk factors underlying ED (hypertension, diabetes, dyslipidaemia, smoking) provides substantial cardiovascular benefit — ED is frequently the presenting symptom of subclinical atherosclerosis, diagnosed 3–5 years before cardiac events.
• Ejaculatory control: Dapoxetine and behavioural techniques produce clinically meaningful, 3–4-fold improvements in IELT and significant improvements in PEDT (Premature Ejaculation Diagnostic Tool) and patient/partner satisfaction scores.
• Curvature correction: CCH injection therapy achieves ~34% reduction in penile curvature vs 18% with placebo (IMPRESS I+II). Surgical correction achieves straightening in >90% of men, restoring sexual function and eliminating psychological impact of visible deformity.
• Hormonal and systemic benefits of TRT: Confirmed improvements in libido, erectile function (when contributing cause is hypogonadism), energy, muscle mass, bone mineral density, mood, and glycaemic control in men with symptomatic hypogonadism.
• Improved relationship and quality of life: Sexual dysfunction imposes significant psychological, interpersonal, and quality-of-life burdens. Successful treatment of any male sexual dysfunction is consistently associated with major improvements in self-esteem, mood, relationship satisfaction, and overall wellbeing.

• PDE5 inhibitors: Potentially fatal hypotension with concurrent nitrates; contraindicated with riociguat. Other side effects: headache, flushing, nasal congestion, myalgia, visual disturbance (especially sildenafil at high doses — non-arteritic anterior ischaemic optic neuropathy, very rare); priapism (<0.5%). Vision or hearing changes should prompt immediate cessation.
• Intracavernosal alprostadil: Penile pain (most common, ~30% of injections); priapism (erection >4 hours — medical emergency requiring aspiration/epinephrine injection); corporal fibrosis with long-term use; bruising at injection site; haematoma; syncope (rare).
• Penile prosthesis: Mechanical failure (~5–7% at 5 years); infection (2–3%; <1% with antibiotic-coated cylinders — InhibiZone coating); erosion; device malposition; autoinflation; revision surgery requirement; irreversibility (residual erectile function is lost).
• Dapoxetine: Nausea (~20%), dizziness, headache, orthostatic hypotension (syncope risk within 4 hours); avoid with other serotonergic drugs (SSRI, SNRI, tramadol, triptans) — serotonin syndrome risk; contraindicated in cardiac disease with QT prolongation, hepatic impairment, MAOIs.
• Collagenase CCH (PD): Penile ecchymosis/bruising (~85%), pain (~61%), swelling, corporal rupture (<1% — requires immediate surgical repair); penile haematoma; lymphadenopathy. Sexual abstinence required for 4 weeks post-injection cycle.
• Testosterone replacement therapy: Polycythaemia/erythrocytosis (haematocrit >54% — requires dose reduction or phlebotomy); infertility (suppresses spermatogenesis); acne; gynaecomastia; testicular atrophy; PSA rise (rule out prostate cancer before TRT); sleep apnoea exacerbation; cardiovascular risk (lipid changes, fluid retention — remain controversial per current evidence); deepening voice in transwomen taking TRT erroneously.

Regular monitoring is essential for all male sexual health treatments:

• PDE5 inhibitors: Review at 4–8 weeks — assess efficacy (IIEF-5 score), tolerability, and whether dose optimisation is needed. Ensure adequate sexual stimulation during trials (minimum 4–6 attempts before declaring treatment failure). Reassess cardiovascular risk annually.
• Intracavernosal alprostadil: Clinic-supervised first injection to titrate dose and ensure patient tolerates treatment and technique. Subsequent review at 3 months; examine for Peyronie's plaque development (fibrosis); limit to ≤3 injections/week, maximum 1 per day.
• Penile prosthesis: Review at 6 weeks (wound check), 3 months (functional assessment), then annually. Educate on inflation/deflation; identify signs of infection (erythema, warmth, device palpable under skin) early.
• Dapoxetine / PE therapy: PEDT score and IELT diary at 4 weeks. Ongoing behavioural therapy co-prescribed; dose escalation to 60 mg if 30 mg provides inadequate response. Annual review for continued need.
• Peyronie's CCH cycles: Penile goniometer curvature measurement before each treatment cycle. Photograph curvature at baseline and after each cycle. Assess PDDU and morning erection quality after cycle completion.
• Testosterone replacement therapy: Testosterone (trough for IM; steady-state for gel), haematocrit/Hb, PSA at 3 months, then 6-monthly. DEXA bone scan at baseline and 2 years. Annual digital rectal examination in men >40. Titrate dose to maintain testosterone 400–700 ng/dL.
• Psychosexual counselling: Regular therapist review during treatment programme; typically 8–16 weekly sessions for CBT-based sexual dysfunction therapy.

Costs vary substantially by country, treatment modality, and healthcare setting:

• PDE5 inhibitors: Generic sildenafil: USD 0.50–2 per tablet in India; USD 2–10 in Europe; USD 15–70 per branded tablet in the US without insurance. Generic tadalafil daily: USD 15–50/month in most markets. Significant price disparity between branded and generic formulations.
• Intracavernosal alprostadil: USD 10–30 per injection (Caverject/Edex) in India and Southeast Asia; USD 70–150 per injection in the United States (branded). Compounded formulations significantly reduce cost.
• Vacuum erection device: USD 50–400 for a quality device; one-time cost; NHS-prescribable in the UK for certain indications.
• Inflatable penile prosthesis (surgery + device): USD 5,000–12,000 in India at accredited centres; USD 18,000–35,000 in the United States (inclusive of facility, anaesthesia, device).
• Dapoxetine: USD 3–8 per tablet (30 mg or 60 mg) in India; USD 10–20 in Europe. Not licensed in the US (available via online pharmacy from abroad).
• Collagenase CCH (Xiaflex) full course: USD 30,000–40,000 in the United States for 8 injections (4 cycles); substantially cheaper in European markets; not available in many countries.
• Testosterone replacement therapy (monthly): USD 20–60 for generic IM testosterone in India; USD 50–200 for transdermal gel; USD 400–1,200 for branded long-acting IM (Nebido/Aveed) injection in high-income countries.
• Initial sexual health workup (hormone panel + STI screen): USD 100–400 in most countries; often subsidised under national sexual health clinic services.

• Low-intensity shockwave therapy (Li-ESWT) for ED: Extracorporeal low-intensity acoustic shockwaves applied to the penis stimulate angiogenesis and neuroregeneration in cavernosal tissue. Evidence supports improvement in mild-to-moderate vasculogenic ED; EAU Guidelines 2023 note promising but still investigational status pending large randomised trials. Advantage: non-invasive, no systemic side effects, potential for disease modification (not just symptomatic relief).
• Platelet-rich plasma (PRP) and stem cell therapy for ED: Emerging therapies with limited phase I/II evidence; not currently recommended outside of clinical trials per major guidelines (EAU, AUA, ISSM).
• Penile arterial revascularisation: Microsurgical arterioplasty (Michal II, Virag V procedures) in young men (<55) with pure arteriogenic ED secondary to a focal arterial lesion (post-traumatic, non-atherosclerotic); specialist centres only; success rates 60–70% in carefully selected patients.
• Psychological therapy (alone for psychogenic ED/PE): CBT and sex therapy are first-line in men with clearly psychogenic or situational ED or PE, particularly when relationship or psychological contributing factors dominate.
• Lifestyle modification: Mediterranean diet, aerobic exercise (150 min/week of moderate intensity), weight loss (a 5% reduction in BMI improves IIEF scores significantly), smoking cessation, and alcohol moderation are evidence-based interventions that improve erectile function and testosterone levels in men with metabolic syndrome and obesity-related ED.
• Traction device therapy (Peyronie's disease): Penile traction devices (RestoreX, Andropenis) used 4–8 hours daily in the acute or stable phase of PD; emerging evidence shows reduction in curvature of 15–25° and penile length restoration when used adjunctively with CCH. Recommended as an adjunct in EAU PD guidelines.